Obviousness

Obviousness Analysis under 35 U.S.C. § 103

This analysis will focus on combinations of prior art that would render the independent claims of US Patent 8501730 obvious to a person having ordinary skill in the art (POSA) as of the priority date of September 2, 2005.

The core of the invention lies in providing improved processes for preparing benzazepine compounds (1), benzoic acid compounds (4), and the pharmaceutically active vasopressin antagonist compounds (10) in high yield and purity on an industrial scale. The patent explicitly states that existing methods for compounds (1) and (4) were not suitable for industrial production due to low yield, low purity, or difficulty in obtaining starting materials.

Motivation to Combine Prior Art

A POSA in the field of pharmaceutical organic chemistry would be motivated to combine known chemical reactions and processes to achieve more efficient, higher-yielding, and purer synthetic routes for pharmaceutically relevant compounds, particularly when existing methods are acknowledged as being industrially unsuitable. The patent itself highlights the problems with prior art processes, creating a clear motivation for improvement.

Obviousness Combinations

Combination 1: JP-A-4-154765 and Kazumi Kondo et al. (1999) rendering Claim 1 obvious.

• Prior Art:

  • JP-A-4-154765: This patent is explicitly cited in US8501730 as disclosing that benzazepine compounds of formula (1) are useful intermediates for preparing pharmaceutically active benzazepine compounds with vasopressin antagonistic activity, specifically compounds (10). It also discloses methods for preparing compounds (1) via Reaction Schemes A and B, although US8501730 states these methods are not suitable for industrial scale due to issues with yield and purity or difficulty in obtaining starting materials.
  • Kazumi Kondo et al., Bioorganic & Medicinal Chemistry 7 (1999), pp. 1743-1754: This publication is also explicitly cited in US8501730 as disclosing a method for preparing benzazepine compounds (1) (Reaction Scheme B).
  • Yasuhiro Torisawa et al., Bioorganic & Medicinal Chemistry Letters, 10(2000), pp. 2493-2495: This publication is cited in US8501730 as disclosing a process for preparing benzoic acid compounds (4) via Reaction Scheme C.

• Claim 1: This claim covers a process for producing a benzazepine compound of formula (1) by reacting a benzazepine compound of formula (2) with an amide compound of formula (3) in the presence of a carbonylating agent.

• Reasoning for Obviousness:

  • JP-A-4-154765 and Kondo (1999) both teach the synthesis of benzazepine compounds (1) and their utility as intermediates for vasopressin antagonists (10). While the '730 patent criticizes these methods for industrial scale, the general reaction types (coupling of a benzazepine core with a substituted benzoic acid derivative) were known.
  • A POSA, faced with the known utility of compounds (1) and the stated deficiencies of existing synthetic routes (low yield, purity, or inaccessible starting materials), would be motivated to find improved synthetic processes.
  • The '730 patent's Reaction Scheme I (Claim 1) describes a carbonylation reaction between compounds (2) and (3). Carbonylation reactions are well-established in organic synthesis for forming carbon-carbon bonds, particularly in the presence of transition metal catalysts like palladium compounds and phosphine ligands. The '730 patent specifically mentions palladium compounds (e.g., palladium acetate) and phosphoric compounds (e.g., triphenylphosphine) as catalysts.
  • Given the general knowledge of carbonylation reactions and the motivation to improve the synthesis of compound (1), a POSA would have a reasonable expectation of success in exploring such a route, even if the specific combination of reagents and conditions might require some optimization. The patent itself provides the detailed conditions for this process, which a POSA could implement or adapt.

Combination 2: JP-A-4-154765 and Yasuhiro Torisawa et al. (2000) rendering Claims 2-5 obvious.

• Prior Art:

  • JP-A-4-154765: As discussed above, this patent discloses the utility of benzoic acid compounds (4) as intermediates for pharmaceutically active vasopressin antagonists.
  • Yasuhiro Torisawa et al., Bioorganic & Medicinal Chemistry Letters, 10(2000), pp. 2493-2495: This publication explicitly teaches a process for preparing benzoic acid compounds (4) (Reaction Scheme C in US8501730).

• Claims 2-5: These claims describe various processes for producing benzoic acid compounds of formula (4) through reactions involving amide compounds (11), (12), (13), or (14), including reactions with oxalyl halides, oxidation, and hydrolysis.

• Reasoning for Obviousness:

  • The Torisawa (2000) paper directly discloses a method for preparing benzoic acid compounds (4). JP-A-4-154765 also highlights the utility of these compounds.
  • Claims 2-5 of US8501730 propose alternative or refined methods for synthesizing compound (4). A POSA, having access to the Torisawa (2000) method and understanding the importance of compound (4) (from JP-A-4-154765), would be motivated to explore different synthetic strategies to improve yield, purity, or efficiency, especially if the existing method had limitations for industrial scale (as implicitly suggested by the '730 patent's objective to provide an improved process for compound (4) on industrial scale).
  • The specific reactions recited in Claims 2-5 (reaction with oxalyl halide, oxidation, and hydrolysis) are all standard synthetic transformations known to a POSA for modifying functional groups and building molecular complexity. For example:
    • Reacting an amide (11) with an oxalyl halide (19) (Claim 2) is a known method for forming a diketone or related carbonyl structures.
    • Oxidation of an amide compound (12) or (14) (Claims 3 and 5) to form a carboxylic acid is a common synthetic strategy, depending on the nature of the "X3" or the specific structure of (14).
    • Hydrolysis of an amide compound (13) (Claim 4) to yield a carboxylic acid is a fundamental reaction in organic chemistry.
  • The selection of these known reactions to achieve a desired transformation on a known intermediate (4), especially with the explicit motivation to improve industrial applicability, would be considered obvious to a POSA.

Combination 3: JP-A-4-154765, Kazumi Kondo et al. (1999), and general knowledge of reduction chemistry rendering Claim 6 obvious.

• Prior Art:

  • JP-A-4-154765: Discloses the transformation of compound (1) into compound (10), where compound (10) is a pharmaceutically active vasopressin antagonist.
  • Kazumi Kondo et al., Bioorganic & Medicinal Chemistry 7 (1999), pp. 1743-1754: Also relevant for the synthesis of compound (1), which serves as the starting material for compound (10).

• Claim 6: This claim describes a process for producing a 2,3,4,5-tetrahydro-1H-1-benzazepine compound of formula (10) by reducing a benzazepine compound of formula (1) using a hydrogenating agent in an amount of 0.1 to 1 mole per 1 mole of compound (1).

• Reasoning for Obviousness:

  • The '730 patent states that compound (1) is converted to compound (10) by reduction with a hydrogenating agent. This general transformation is known from JP-A-4-154765.
  • The inventive step in Claim 6 lies in the specific amount of hydrogenating agent (0.1 to 1 mole per 1 mole of compound (1)), and the assertion that this specific range allows the reaction to proceed with "hardly occurring undesirable dehalogenating reaction."
  • However, a POSA would understand that controlling stoichiometry is a routine aspect of optimizing chemical reactions to favor desired products and minimize side reactions. Given that hydrogenating agents are well-known to perform reductions, and that excessive reducing agent can lead to over-reduction or side reactions like dehalogenation, a POSA would routinely experiment with varying amounts of reducing agent, including sub-stoichiometric or carefully controlled stoichiometric amounts, to achieve selectivity.
  • The patent itself lists common hydrogenating agents such as lithium aluminum hydride, sodium borohydride, zinc borohydride, and diborane. These are standard reagents in organic synthesis for the reduction of ketones (the transformation from compound (1) to (10) involves the reduction of a ketone to an alcohol).
  • Therefore, optimizing the amount of a known reducing agent to achieve selective reduction and minimize side reactions, even dehalogenation, would be considered routine experimentation and well within the skill of a POSA, especially with the known goal of producing compound (10) from compound (1). The identified range, while perhaps an optimal finding, is a result of routine experimentation rather than an inventive concept.

Conclusion on Obviousness

Based on the explicit admissions in the '730 patent regarding the existence and utility of prior art compounds and synthetic pathways (JP-A-4-154765, Kondo (1999), Torisawa (2000)), and the common knowledge of synthetic organic chemistry, a POSA would have been motivated to combine these teachings and apply routine experimentation to develop the processes claimed in US8501730. The claims represent improvements in yield and purity, and while valuable, these improvements stem from the optimization of known reactions and conditions rather than a fundamentally new chemical process, making them vulnerable to obviousness challenges. This is further supported by the Federal Circuit's affirmation of invalidity over the Kondo (1999) paper in the Otsuka Pharmaceutical Co. v. Lupin Ltd. case for the asserted method claims.